F-1/A: Polyrizon Ltd. Eyes Nasdaq Listing with Proposed $5.20 Unit Offering

Polyrizon Ltd., a biotech firm specializing in nasal spray hydrogels, aims to raise capital through an initial public offering with units priced at $5.20, each including one ordinary share and three warrants.

Summary

• Polyrizon Ltd., an Israeli biotech company, is planning an initial public offering (IPO) to list its ordinary shares on the Nasdaq Capital Market under the ticker symbol PLRZ.
• The company is offering 807,692 units, each consisting of one ordinary share and three warrants, with an anticipated IPO price between $4.38 and $6.02 per unit.
• The assumed exercise price of each warrant is $5.20 per ordinary share.
• Polyrizon is also offering pre-funded units to purchasers who would otherwise exceed ownership limits of 4.99% or 9.99% of the company's outstanding ordinary shares.
• Each pre-funded unit consists of a pre-funded warrant to purchase one ordinary share and three warrants, with the purchase price of each pre-funded unit being the price per unit minus $0.001, and the exercise price of each pre-funded warrant being $0.001 per ordinary share.
• The company has applied to list its ordinary shares on the Nasdaq Capital Market, and the closing of the offering is conditional upon this listing being approved.
• Certain existing shareholders have indicated an interest in purchasing up to $1 million of units in the offering.
• The underwriter has an option to purchase up to an additional 121,153 ordinary shares, 363,461 warrants, or 121,153 pre-funded warrants within 45 days to cover over-allotments.
• The company expects to receive approximately $3.4 million in net proceeds from the offering, or $4.0 million if the underwriter exercises its over-allotment option in full.
• The company plans to use the net proceeds to complete preclinical and clinical development of its PL-14, PL-15, and PL-16 product candidates, complete in vitro feasibility studies for its T&T platform technology product candidates, repay convertible loan agreements, and for working capital and general corporate purposes.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of Polyrizon's technology and the risks associated with its development and commercialization. The company's reliance on future funding and the uncertainties surrounding regulatory approvals contribute to a neutral sentiment.

Positives

• The company has a clear plan for using the proceeds from the IPO.
• The company has secured interest from existing shareholders to purchase a significant portion of the offering.
• The company's products address large and growing markets, such as allergic rhinitis and nasal viral infections.

Negatives

• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• The company has never generated any revenue from product candidate sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company is heavily dependent on the success of its C&C product candidates.
• The company has not previously conducted pivotal clinical trials.
• The company relies on third parties to manufacture the raw materials that it uses to create its product candidates.

Risks

• The company's financial condition and capital requirements pose risks, including the need for substantial additional funding.
• The company faces risks related to the discovery, development, and clinical testing of product candidates, including potential delays and regulatory hurdles.
• The company relies on third parties, which introduces risks related to their performance and compliance.
• The company faces risks related to its intellectual property, including the ability to obtain and maintain effective patent rights.
• The company's business operations are subject to risks, including difficulties in managing growth and potential misconduct by employees.
• The company faces risks related to the commercialization of its product candidates, including the need to establish marketing and sales capabilities.
• The company is subject to risks related to this offering and ownership of its securities, including potential volatility and dilution.
• The company's operations in Israel are subject to risks related to political, economic, and military instability.
• The company may be subject to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws.

Future Outlook

The company expects expenses and operating losses to increase for the foreseeable future as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The document highlights the increasing market for nasal sprays and drug delivery systems, particularly for allergic rhinitis, viral infections, and pain management, indicating a growing demand for innovative solutions in these areas.

Comparison to Industry Standards

• The document mentions Alzair Allergy Blocker, NASAL EASE ALLERGY BLOCKER, and Bentrio Allergy Blocker as predicate devices for the PL-14 product candidate, providing a benchmark for regulatory approval timelines.
• The document references the World Health Organization's Global Influenza Strategy 2019-2030 and statistics on COVID-19 fatalities to contextualize the market need for Polyrizon's C&C technology.
• The document cites market research reports from Fortune Business Insights, Transparency Market Research, Global Market Insights, Infinium Global Research, The Brainy Insights, Future Market Insight, Polaris Market Research, Custom Market Insight, and Vantage Market Research to support market size and growth estimates for various indications.

Related Party Transactions

• The document discloses several related party transactions, including share purchase agreements and convertible loan agreements with XYLO Technologies Ltd. and other principal shareholders.
• The document discloses that certain existing shareholders have indicated an interest in purchasing up to $1 million of units in the offering.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the offering and the risks associated with the company's business.
• Employees may be impacted by the company's ability to secure funding and execute its business plan.
• Customers may benefit from the development of new and innovative products.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Initiate preclinical safety trials for PL-14, PL-15, and PL-16 product candidates in the second quarter of 2025.
• Commence pivotal clinical trial on PL-14 product candidate in the fourth quarter of 2025.
• Submit a 510(k) application for FDA clearance for PL-14 product candidate.
• Initiate feasibility clinical trials for PL-15 product candidate in the third quarter of 2026.
• Initiate pivotal clinical trials for PL-15 product candidate in the second quarter of 2027.
• Submit a De Novo Classification request for PL-15 product candidate.
• Initiate feasibility clinical trials for PL-16 product candidate in the first quarter of 2026.
• Initiate pivotal clinical trials for PL-16 product candidate in the third quarter of 2026.
• Submit a De Novo Classification request for PL-16 product candidate.
• Conduct feasibility studies for T&T platform product candidates with corticosteroids, benzodiazepines, and naloxone, beginning in the fourth quarter of 2024 through the first quarter of 2026.
• Begin pre-clinical studies for T&T platform product candidates in the second quarter of 2026.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2027.
• Start initial testing to explore the potential of the SCI-160 platform when combined with the T&T technology, in the first quarter of 2025.

Key Dates

Keywords

IPO, Polyrizon, Units, Warrants, Pre-Funded Units, Nasal Spray, Hydrogels, Biotech, Clinical Trials, FDA, PLRZ